Kora Saúde Participações Past Earnings Performance
Past criteria checks 0/6
Kora Saúde Participações's earnings have been declining at an average annual rate of -48.9%, while the Healthcare industry saw earnings growing at 21.6% annually. Revenues have been growing at an average rate of 29.3% per year.
Key information
-48.9%
Earnings growth rate
-47.6%
EPS growth rate
| Healthcare Industry Growth | 11.6% |
| Revenue growth rate | 29.3% |
| Return on equity | -8.0% |
| Net Margin | -4.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Kora Saúde Participações S.A.'s (BVMF:KRSA3) Shares Climb 26% But Its Business Is Yet to Catch Up
Nov 06
Returns On Capital Signal Tricky Times Ahead For Kora Saúde Participações (BVMF:KRSA3)
Oct 28Kora Saúde Participações S.A.'s (BVMF:KRSA3) Business And Shares Still Trailing The Industry
Sep 21Revenues Working Against Kora Saúde Participações S.A.'s (BVMF:KRSA3) Share Price Following 25% Dive
Jun 13Does Kora Saúde Participações (BVMF:KRSA3) Have A Healthy Balance Sheet?
May 23Why Investors Shouldn't Be Surprised By Kora Saúde Participações S.A.'s (BVMF:KRSA3) 26% Share Price Plunge
Apr 16Little Excitement Around Kora Saúde Participações S.A.'s (BVMF:KRSA3) Revenues As Shares Take 25% Pounding
Feb 06There Are Reasons To Feel Uneasy About Kora Saúde Participações' (BVMF:KRSA3) Returns On Capital
Jan 17Kora Saúde Participações S.A. (BVMF:KRSA3) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 05Should You Investigate Kora Saúde Participações S.A. (BVMF:KRSA3) At R$1.17?
Sep 07Kora Saúde Participações' (BVMF:KRSA3) Returns On Capital Not Reflecting Well On The Business
Jul 24Returns On Capital Signal Tricky Times Ahead For Kora Saúde Participações (BVMF:KRSA3)
Jan 10Kora Saúde Participações S.A. (BVMF:KRSA3) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Apr 04Revenue & Expenses Breakdown
How Kora Saúde Participações makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,276 | -91 | 170 | 0 |
| 30 Jun 24 | 2,289 | -111 | 163 | 0 |
| 31 Mar 24 | 2,272 | -145 | 170 | 0 |
| 31 Dec 23 | 2,260 | -168 | 193 | 0 |
| 30 Sep 23 | 2,233 | -212 | 211 | 0 |
| 30 Jun 23 | 2,167 | -222 | 238 | 0 |
| 31 Mar 23 | 2,121 | -173 | 264 | 0 |
| 31 Dec 22 | 2,047 | -108 | 225 | 0 |
| 30 Sep 22 | 1,923 | -122 | 254 | 0 |
| 30 Jun 22 | 1,736 | -83 | 231 | 0 |
| 31 Mar 22 | 1,524 | -62 | 181 | 0 |
| 31 Dec 21 | 1,262 | -64 | 175 | 0 |
| 30 Sep 21 | 1,029 | 14 | 118 | 0 |
| 30 Jun 21 | 860 | 41 | 95 | 0 |
| 31 Mar 21 | 689 | 28 | 83 | 0 |
| 31 Dec 20 | 612 | 16 | 83 | 0 |
| 31 Dec 19 | 442 | -3 | 67 | 0 |
| 31 Dec 18 | 283 | 1 | 136 | 0 |
| 31 Dec 17 | 264 | 6 | 118 | 0 |
Quality Earnings: KRSA3 is currently unprofitable.
Growing Profit Margin: KRSA3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KRSA3 is unprofitable, and losses have increased over the past 5 years at a rate of 48.9% per year.
Accelerating Growth: Unable to compare KRSA3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KRSA3 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (64.3%).
Return on Equity
High ROE: KRSA3 has a negative Return on Equity (-8.03%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 10:37 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kora Saúde Participações S.A. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
| Gustavo Miele | Goldman Sachs |
| Gustavo Miele | Itau BBA |